Centre for Sleep Science, School of Human Sciences, University of Western Australia, Crawley, WA, Australia.
Department of Pulmonary Physiology & Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Sleep. 2022 Apr 11;45(4). doi: 10.1093/sleep/zsab264.
Randomized controlled trials (RCTs) have shown no reduction in adverse cardiovascular (CV) events in patients randomized to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA). This study examined whether randomized study populations were representative of OSA patients attending a sleep clinic.
Sleep clinic patients were 3,965 consecutive adults diagnosed with OSA by in-laboratory polysomnography from 2006 to 2010 at a tertiary hospital sleep clinic. Characteristics of these patients were compared with participants of five recent RCTs examining the effect of CPAP on adverse CV events in OSA. The percentage of patients with severe (apnea-hypopnea index, [AHI] ≥ 30 events/h) or any OSA (AHI ≥ 5 events/h) who met the eligibility criteria of each RCT was determined, and those criteria that excluded the most patients identified.
Compared to RCT participants, sleep clinic OSA patients were younger, sleepier, more likely to be female and less likely to have established CV disease. The percentage of patients with severe or any OSA who met the RCT eligibility criteria ranged from 1.2% to 20.9% and 0.8% to 21.9%, respectively. The eligibility criteria that excluded most patients were preexisting CV disease, symptoms of excessive sleepiness, nocturnal hypoxemia and co-morbidities.
A minority of sleep clinic patients diagnosed with OSA meet the eligibility criteria of RCTs of CPAP on adverse CV events in OSA. OSA populations in these RCTs differ considerably from typical sleep clinic OSA patients. This suggests that the findings of such OSA treatment-related RCTs are not generalizable to sleep clinic OSA patients.Randomized Intervention with Continuous Positive Airway Pressure in CAD and OSA (RICCADSA) trial, https://clinicaltrials.gov/ct2/show/NCT00519597, ClinicalTrials.gov number, NCT00519597.Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients with a First Ever Stroke and Sleep Apnea Syndrome, https://clinicaltrials.gov/ct2/show/NCT00202501, ClinicalTrials.gov number, NCT00202501.Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients with Sleep Apnea and no Daytime Sleepiness, https://clinicaltrials.gov/ct2/show/NCT00127348, ClinicalTrials.gov number, NCT00127348.Continuous Positive Airway Pressure (CPAP) in Patients with Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA) (ISAACC), https://clinicaltrials.gov/ct2/show/NCT01335087, ClinicalTrials.gov number, NCT01335087.
随机对照试验(RCT)表明,对于阻塞性睡眠呼吸暂停(OSA)患者,连续气道正压通气(CPAP)治疗并未降低不良心血管(CV)事件的发生。本研究旨在探讨随机研究人群是否代表了接受睡眠诊所治疗的 OSA 患者。
2006 年至 2010 年,在一家三级医院睡眠诊所,通过实验室多导睡眠图对连续 3965 例经诊断患有 OSA 的成年患者进行随机分组。将这些患者的特征与五项近期 RCT 中 CPAP 对 OSA 不良 CV 事件影响的研究参与者进行比较。确定严重(呼吸暂停-低通气指数[AHI]≥30 次/小时)或任何 OSA(AHI≥5 次/小时)患者中符合每项 RCT 入选标准的比例,并确定排除最多患者的入选标准。
与 RCT 参与者相比,睡眠诊所 OSA 患者更年轻、更嗜睡、更可能为女性且不太可能患有已确诊的 CV 疾病。符合 RCT 入选标准的严重或任何 OSA 患者的比例分别为 1.2%至 20.9%和 0.8%至 21.9%。排除大多数患者的入选标准为既往 CV 疾病、过度嗜睡症状、夜间低氧血症和合并症。
在睡眠诊所诊断为 OSA 的患者中,只有少数符合 RCT 中 CPAP 治疗 OSA 不良 CV 事件的入选标准。这些 RCT 中的 OSA 人群与典型的睡眠诊所 OSA 患者有很大差异。这表明,此类与 OSA 治疗相关的 RCT 结果不能推广至睡眠诊所的 OSA 患者。
随机干预性持续气道正压通气在 CAD 和 OSA 中的应用研究(RICCADSA)试验,https://clinicaltrials.gov/ct2/show/NCT00519597,ClinicalTrials.gov 编号,NCT00519597。
首次发生中风和睡眠呼吸暂停综合征患者中经鼻持续气道正压通气(CPAP)治疗的有效性研究,https://clinicaltrials.gov/ct2/show/NCT00202501,ClinicalTrials.gov 编号,NCT00202501。
持续气道正压通气(CPAP)对伴有睡眠呼吸暂停且无日间嗜睡的高血压和心血管发病率-死亡率的影响研究,https://clinicaltrials.gov/ct2/show/NCT00127348,ClinicalTrials.gov 编号,NCT00127348。
急性冠状动脉综合征和阻塞性睡眠呼吸暂停(OSA)患者中的持续气道正压通气(CPAP)(ISAACC)研究,https://clinicaltrials.gov/ct2/show/NCT01335087,ClinicalTrials.gov 编号,NCT01335087。